Is Apelix officially launched in China? Domestic launch time and approval progress

Alpelisib (Alpelisib) has not yet been officially launched in China, and domestic patients cannot purchase the drug domestically through formal channels. Although Apelvis is an important targeted drug that has significant efficacy in the treatment of certain types of breast cancer, especially breast cancer patients with PI3K mutation-positive breast cancer, the Chinese drug regulatory agency has not yet approved its domestic marketing. Regarding the approval progress of Apelvis, although there is some clinical trial data and market demand, the specific launch time is still uncertain, and patients need to continue to wait for the approval process of domestic regulatory authorities.

At present, the original drug of Apelvis is mainly supplied through overseas channels, and domestic patients can obtain it through these channels. The price of the Indian version of the original Apelvis drug in the Indian market is approximately more than 3,000 yuan. However, since the drug has not yet been approved in the Chinese market, domestic patients need to rely on international drug purchase channels. While this purchasing method has provided medicines for some patients, there are certain risks, including issues with the authenticity and quality of the medicines.

In addition to the original drug, generic drugs of Apelvis are also on the market in some countries, and their prices are much more advantageous than those of the original drug. Taking India as an example, the price of the imitation version of Apelis is around more than 1,000 yuan. Generic drugs are basically the same as the original drugs in terms of ingredients and efficacy. For patients with limited financial conditions, generic drugs are undoubtedly a more affordable option. However, generic drugs also need to be purchased through formal channels to avoid purchasing products of substandard quality.

In general, Apelvis is not yet available in China, and domestic patients can currently only purchase it through overseas channels. As the demand for this drug increases from more patients and the domestic drug approval process advances, the launch of Apelvis in China may receive further attention in the future. Patients should choose a reasonable purchase channel based on the doctor's advice and their own situation, and always pay attention to the relevant approval progress.

Reference materials:https://www.piqray.com/